OBCTCD24
Exosome-delivered CD24-based Therapeutics
Company Overview
Snapshot
Founded in August 2020, OBCTCD24 operates with 1–10 employees. The company ceased operations in December 2021.
Business overview
OBCTCD24 is a clinical-stage biopharmaceutical company focused on developing exosome-delivered, CD24-based therapeutics. This new class of medicines aims to transform the treatment of a wide spectrum of diseases with high unmet medical need. The company operates within the Health Tech & Life Sciences sector, specifically in Pharmaceuticals, targeting areas like autoimmune diseases, drug development, and respiratory conditions.
Strategic signal
In April 2021, an Israeli hospital associated with OBCTCD24 claimed to have found a cure for COVID-19. This news, while potentially significant for public health, signals a high-risk, high-reward profile for the company's therapeutic approach, indicating a focus on urgent global health challenges and the potential for rapid, impactful breakthroughs if validated.
Log in to access full profile ›Company Intelligence Q&A
- What is OBCTCD24's primary focus?
- OBCTCD24 is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-delivered, CD24-based therapeutics.
- When was OBCTCD24 founded?
- OBCTCD24 was founded in August 2020.
- What is the operational status of OBCTCD24?
- OBCTCD24 is currently non-active, having ceased operations in December 2021.
- What was a notable claim made in April 2021 regarding OBCTCD24's work?
- In April 2021, an Israeli hospital claimed to have found a cure for COVID-19, which was associated with OBCTCD24's research.
- What industries does OBCTCD24 target?
- OBCTCD24 targets the biopharmaceutical industry, focusing on drug development for conditions such as autoimmune diseases and respiratory illnesses.